Previous 10 | Next 10 |
DBV Technologies press release (NASDAQ:DBVT): Q1 GAAP EPS of -$0.30 beats by $0.10. Revenue of $2.55M (-13.3% Y/Y) beats by $1.27M. For further details see: DBV Technologies GAAP EPS of -$0.30 beats by $0.10, revenue of $2.55M beats by $1.27M
Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol ...
AGNC, AMKR, AMRC, ANET, AWR, BGCP, BIGC, BRX, BSM, BXP, CACC, CAR, CBT, CC, CDLX, CHGG, CLX, CSR, CTRA, CVI, DBVT, OTCPK:DOCRF, DVN, DZSI, EARN, EVER, EXPE, FANG, FLS, FMC, FN, FRPT, GAIA, HLIT, HVT, IPI, LEG, LOGI, MED, OTCPK:MEGEF, MGM, MOS, MPWR, MWA, NE, NTR, NXPI, OHI, ORA, OTTR, OUT, PS...
Montrouge, France, April 26, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...
Montrouge, France, April 25, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...
Montrouge, France, April 21, 2022 Ordinary and Extraordinary General Meeting of May 12 , 2022 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DB...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
Shares of DBV Technologies S.A. (NASDAQ:DBVT) traded at a new 52-week high today of $50.24. So far today approximately 39.1 million shares have been exchanged, as compared to an average 30-day volume of 154,000 shares. DBV Technologies S.A. has overhead space with shares priced $1.45, or...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Hycroft Mining (NASDAQ:HYMC) +84% AMC Entertainment is buying 22% of Hycroft Mining Holding. Incannex Healthcare (NASDAQ:IXHL) +66%. Excellon Resources (NYSE:EXN) +23%. Hollysys Automation Technologies (NASDAQ:HOLI) +12%. Anavex Life Sciences (NASDAQ:AVXL) +9% posts mid-st...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa...
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 *...